Yüklüyor......
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study,...
Kaydedildi:
| Yayımlandı: | Clin Transl Sci |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7719384/ https://ncbi.nlm.nih.gov/pubmed/32453913 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12809 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|